Neurocritical care in the era of COVID-19 Part 3
The COVID-19 pandemic has immensely changed the landscape of healthcare. Dr. Kevin Sheth shares his insights about the management and treatment of neurocritically ill patients with COVID-19.
Dr Sheth discloses personal compensation for royalty, license fees, or contractual rights payments from Alva Health. His institution (Yale) has received research support from Biogen, Novartis, Bard, Hyperfine.